Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ATN-161 in Advanced Renal Cell Cancer


A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer




The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.

Study Status: Terminated


Condition Intervention Phase
Carcinoma, Renal Cell Drug: ATN-161 Phase 2

Verified by Attenuon December, 2007

Sponsored by: Attenuon
Information provided by: Attenuon identifier: NCT00131651

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Pharmacodynamics Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44165
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site